Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.
Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.
Lacy
Mark D
MD
Parasitic Diseases Program, US Naval Medical Research Unit 2, Jakarta, Indonesia.
Maguire
Jason D
JD
Barcus
Mazie J
MJ
Ling
Judith
J
Bangs
Michael J
MJ
Gramzinski
Robert
R
Basri
Hasan
H
Sismadi
Priyanto
P
Miller
Gerri B
GB
Chulay
Jeffrey D
JD
Fryauff
David J
DJ
Hoffman
Stephen L
SL
Baird
J Kevin
JK
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D053626:Atovaquone; D004311:Double-Blind Method; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007214:Indonesia / Q000453:epidemiology; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000276:immunology; D016780:Malaria, Vivax / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009285:Naphthoquinones / Q000627:therapeutic use*; D010963:Plasmodium falciparum / Q000187:drug effects; D010966:Plasmodium vivax / Q000187:drug effects; D002727:Proguanil / Q000627:therapeutic use*; D016896:Treatment Outcome
D000962:Antimalarials; D009285:Naphthoquinones; D002727:Proguanil; D053626:Atovaquone